PMC3628261_01
The single photon emission tomography-computed tomography (SPECT-CT) scan shows iodine-concentrating lesion in left gluteal muscle
IJNM-27-38-g001.jpg
PMC3628261_01_IJNM-27-38-g001.jpg
F1
During the follow-up, prompted by elevated thyroglobulin levels, an iodine-131 whole body scan and single photon emission tomography-computed tomography (SPECT-CT) [Figure 1] showed positive lesions, one in the liver and another in the left gluteal region.
Left gluteal lesions were metabolically active in pretherapy positron emission tomography-computed tomography (PET-CT) study
IJNM-27-38-g002.jpg
PMC3628261_01_IJNM-27-38-g002.jpg
F2
A fludeoxyglucose (FDG) PET-CT scan [Figure 2] was done to find more lesions and revealed metabolically active lesions in liver segment VI [Figure 3] and the left gluteus and a new paraspinal muscle lesion at the nape of the neck [Figure 4], whereas the lung nodules were metabolically inactive [Figure 5].
The liver
IJNM-27-38-g003.jpg
PMC3628261_01_IJNM-27-38-g003.jpg
F3
A fludeoxyglucose (FDG) PET-CT scan [Figure 2] was done to find more lesions and revealed metabolically active lesions in liver segment VI [Figure 3] and the left gluteus and a new paraspinal muscle lesion at the nape of the neck [Figure 4], whereas the lung nodules were metabolically inactive [Figure 5].
The new lesion at nape of neck
IJNM-27-38-g004.jpg
PMC3628261_01_IJNM-27-38-g004.jpg
F4
A fludeoxyglucose (FDG) PET-CT scan [Figure 2] was done to find more lesions and revealed metabolically active lesions in liver segment VI [Figure 3] and the left gluteus and a new paraspinal muscle lesion at the nape of the neck [Figure 4], whereas the lung nodules were metabolically inactive [Figure 5].
Fludeoxyglucose (FDG) activity but not lung nodules
IJNM-27-38-g005.jpg
PMC3628261_01_IJNM-27-38-g005.jpg
F5
A fludeoxyglucose (FDG) PET-CT scan [Figure 2] was done to find more lesions and revealed metabolically active lesions in liver segment VI [Figure 3] and the left gluteus and a new paraspinal muscle lesion at the nape of the neck [Figure 4], whereas the lung nodules were metabolically inactive [Figure 5].
The 200 mci post-therapy scan
IJNM-27-38-g006.jpg
PMC3628261_01_IJNM-27-38-g006.jpg
F6
A post-therapy scan [Figure 6] at a therapeutic dose of 200 mci of iodine-131 revealed iodine concentration in the liver and a gluteal lesion, whereas there was no concentration in lung nodules and neck lesion.
Concentration in liver and gluteal lesion but no concentration in neck lesion and lung nodules. The positron emission tomography-computed tomography (PET-CT) scan after six months
IJNM-27-38-g007.jpg
PMC3628261_01_IJNM-27-38-g007.jpg
F7
PET CT scan [Figure 7] as a response evaluation six month post treatment revealed a metabolic response in the liver and gluteal lesion [Figure 8], but an increasing size of the neck lesion [Figure 9] and lung nodules [Figure 10]. Presently, the patient is put on redifferentiation therapy with sorafenib and suppressive doses of thyroxin.
Iodine therapy shows treatment response in liver
IJNM-27-38-g008.jpg
PMC3628261_01_IJNM-27-38-g008.jpg
F8
PET CT scan [Figure 7] as a response evaluation six month post treatment revealed a metabolic response in the liver and gluteal lesion [Figure 8], but an increasing size of the neck lesion [Figure 9] and lung nodules [Figure 10]. Presently, the patient is put on redifferentiation therapy with sorafenib and suppressive doses of thyroxin.
Soft tissue deposit in the neck demonstrating increase in size and FDG uptake (Disease Progression)
IJNM-27-38-g009.jpg
PMC3628261_01_IJNM-27-38-g009.jpg
F9
PET CT scan [Figure 7] as a response evaluation six month post treatment revealed a metabolic response in the liver and gluteal lesion [Figure 8], but an increasing size of the neck lesion [Figure 9] and lung nodules [Figure 10]. Presently, the patient is put on redifferentiation therapy with sorafenib and suppressive doses of thyroxin.
Lung nodules
IJNM-27-38-g010.jpg
PMC3628261_01_IJNM-27-38-g010.jpg
F10
PET CT scan [Figure 7] as a response evaluation six month post treatment revealed a metabolic response in the liver and gluteal lesion [Figure 8], but an increasing size of the neck lesion [Figure 9] and lung nodules [Figure 10]. Presently, the patient is put on redifferentiation therapy with sorafenib and suppressive doses of thyroxin.